Biogen Inc. with ticker code (BIIB) have now 27 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 398 and 263 and has a mean target at $332.26. Given that the stocks previous close was at $310.56 this is indicating there is a potential upside of 7.0%. Also worth taking note is the 50 day moving average now sits at $283.92 and the 200 moving average now moves to $266.49. The market capitalization for the company is 45.34B. The current share price for the company is: 309.6 USD
The potential market cap would be $48,510,053,670 based on the market consensus.
USD
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 14.45, revenue per share of 69.87 and a 7.49% return on assets.
